Image Description

INVESTORS
& MEDIA

circle

INVESTOR OVERVIEW

There are currently no events to display.

Cytokinetics is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. As a leader in muscle biology and the mechanics of muscle performance, the company is developing small molecule drug candidates specifically engineered to increase muscle function and contractility. CytokineticMore >>

ANNUAL REPORT

CORPORATE PRESENTATION

CYTOKINETICS FACT SHEETS

fact1

Company

09/21/18
( FY )
ALS

ALS

07/13/18
( FY )
SMA

SMA

07/13/18
( FY )

NEWS

Date Title and Summary
Toggle Summary Cytokinetics to Present at the Morgan Stanley Global Healthcare Conference
SOUTH SAN FRANCISCO, Calif. , Sept. 05, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (Nasdaq: CYTK) today announced that Robert I. Blum , President and Chief Executive Officer, is scheduled to present a corporate update at the 16 th Annual Morgan Stanley Global Healthcare Conference on Wednesday,
Toggle Summary Cytokinetics Awards Inaugural Communications Fellowship To The ALS Association Golden West Chapter
SOUTH SAN FRANCISCO, Calif. , Aug. 28, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that The ALS Association Golden West Chapter is the inaugural recipient of the Cytokinetics Communications Fellowship, an annual grant from the company intended to support
Toggle Summary Cytokinetics, Inc. Reports Second Quarter 2018 Financial Results
Phase 2 Study of Reldesemtiv in Patients with SMA  Showed Potentially Clinically Meaningful Effects  on Six Minute Walk Distance and Maximal Expiratory Pressure Results from Phase 2 Clinical Trial of Reldesemtiv in Patients with COPD Expected in Q3 Finalizing Preparations to Initiate Second Phase 3
Toggle Summary Cytokinetics to Announce Second Quarter Results on July 26, 2018
SOUTH SAN FRANCISCO, Calif. , July 12, 2018 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq:CYTK) today announced that it is scheduled to report second quarter results on July 26, 2018 at 4:00 PM Eastern Time . Following the announcement, Cytokinetics’ senior management will host a

EVENTS

There are currently no events to display.